Remission Rates Following Antidepressant Therapy With Bupropion or Selective Serotonin Reuptake Inhibitors
| Autor: | Carol B. Rockett, April E. Harriett, Michael E. Thase, Melinda Mitton, Susan VanMeter, Nathalie Richard, Younghua Wang, Barbara R. Haight, Jack G. Modell |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Bupropion
Depressive Disorder Major Fluoxetine Sertraline medicine.medical_specialty Dopamine reuptake inhibitor Pharmacology medicine.disease Placebo Paroxetine Psychiatry and Mental health Treatment Outcome Tolerability Internal medicine mental disorders medicine Antidepressive Agents Second-Generation Humans Major depressive disorder Psychology Selective Serotonin Reuptake Inhibitors Randomized Controlled Trials as Topic medicine.drug |
| Zdroj: | The Journal of Clinical Psychiatry. 66:974-981 |
| ISSN: | 0160-6689 |
| Popis: | Background: Although it is widely believed tha the various classes of antidepressants are equally effective, clinically meaningful differences may be obscured in individual studies because of a lack of statistical power. The present report describes a meta-analysis of original data from a complete set of studies comparing the norepinephrine/dopamine reuptake inhibitor (NDRI) bupropion with selective serotonin reuptake inhibitors (SSRIs; sertraline, fluoxetine, or paroxetine). Method: Individual patient data were pooled from a complete set of 7 randomized, double-blind studies comparing bupropion (N = 732) with SSRIs (fluoxetine, N = 339; sertraline, N = 343; paroxetine, N = 49) in outpatients with major depressive disorder (DSM-III-R or DSM-IV); 4 studies included placebo (N = 512). Response and remission rates were compared at week 8 or endpoint in both the intent-to-treat sample, using the last-observation-carried-forward (LOCF) method to account for attrition, and the observed cases. Tolerability data, including incidence of sexual side effects, were also compared. Results: The LOCF response and remission rates for the bupropion (62% and 47%) and SSRI (63% and 47%) groups were similar; both active therapies were superior to placebo (51% and 36%; all comparisons, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|